Saturday 17 October 2026
Export DRMA’s income statement to Excel — free account
Dermata Therapeutics, Inc.
DRMA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.4% and free cash flow grew 9.99%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.05
−5.49%
Follow DRMA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (183.89%) | (103.58%) | (194.20%) | (203.36%) |
+8 more TTM periods Free account |
|
| (139.93%) | (81.31%) | (132.63%) | (150.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(242.40%) | (110.75%) | (121.45%) | (223.42%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.00) | (2.15) | (8.38) | (9.10) | |
Free Cash Flow |
(8.03) | (8.30) | (7.76) | (9.34) | |
| Other line items | |||||
Cash ROIC |
(101.69%) | (62.16%) | (56.44%) | (108.32%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.96 | 1.17 | 1.03 | 1.06 | |
Depreciation/Fixed assets |
0.00 | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.00) | (2.15) | (8.38) | (9.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates